WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that Chairman and Chief Executive Officer Jonathan Javitt, M.D., M.P.H., will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 p.m. ET.
The company said a live webcast and replay of the session will be made available through its investor relations site. Management will also meet with investors in one-on-one sessions during the conference.
NRx is a clinical-stage biopharmaceutical company focused on therapies for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. Its lead programs include NRX-100, an intravenous ketamine treatment that has received Fast Track designation from the FDA, and NRX-101, an oral therapy that has been granted Breakthrough Therapy designation for suicidal bipolar depression. The company has also advanced regulatory filings for NRX-100, including an Abbreviated New Drug Application and a New Drug Application under the Commissioner’s National Priority Voucher Program.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.